Results provide a mechanistic explanation of why early loss of p53 signaling is frequently observed in UC-associated ...

Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...

A team of researchers led by Kimberly Hartl, a graduate student at the Berlin Institute for Medical Systems Biology of the ...

Researchers have elucidated the role of the p53 gene in ulcerative colitis. The study suggests a potential new drug target to stop disease progression to cancer.

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

New research highlights a pivotal role for the p53 gene in ulcerative colitis progression, offering a potential therapeutic ...

Researchers in the lab of Michael Sigal at the Max Delbrück Center and Charité – Universitätsmedizin Berlin have elucidated ...

US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with ...

The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.

Ulcerative colitis is an inflammatory bowel disease that afflicts an estimated five million people worldwide and that is ...